Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188797 | 0.91 | ALDH1A1 (0.63) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL189326 | 0.91 | ALDH1A1 (0.65) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL15109513 | 0.89 | ALDH1A1 (0.43) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL189483 | 0.89 | ALDH1A1 (0.60) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL189369 | 0.84 | ALDH1A1 (0.63) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL188738 | 0.84 | HSD17B10 (0.63) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL188808 | 0.84 | PIK3CA (0.71) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL1902105 | 0.82 | KDM4E (0.59) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL190097 | 0.81 | KDM4E (0.60) | ALDH1A1MAPK1HSD17B10KDM4EGLA | |
| SCHEMBL12676413 | 0.80 | SRC (0.43) | PIK3CARIPK2ACVR1NOD2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | claimed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| EP-1940839-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | EXELIXIS INC (US) | 2013-07-31 | — | — | EP | claimed |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | EXELIXIS, INC (US) | 2013-07-04 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | claimed |
| EP-2322523-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | claimed |
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-8901137-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors | EXELIXIS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901137-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors | EXELIXIS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | SANOFI (FR) | 2014-10-09 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4075/4885MAPK1 63/4885HSD17B10 2641/4885 |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | ALDH1A1 1153/4885MAPK1 577/4885HSD17B10 904/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4075/4885MAPK1 63/4885HSD17B10 2641/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | ALDH1A1 4089/4885MAPK1 66/4885HSD17B10 2479/4885 |
| US-20140302012-A1 | Combination Therapies for Treating Hematologic Malignancies Using Pyridopyrimidinone Inhibitors of PI3K/mTOR with Bendamustine and/or Rituximab | BTK, MTOR, BCL6 | ALDH1A1 1452/4885MAPK1 275/4885HSD17B10 3254/4885 |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | MTOR, PIK3CA, PIK3CD | ALDH1A1 2766/4885MAPK1 199/4885HSD17B10 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.